Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 41-46

  Kaehler, Katharina C ^a   Sondak, Vernon K ^b,c   Schadendorf, Dirk ^d   Hauschild, Axel ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Adjuvant treatment; Conventional interferon; Immunotherapy; Malignant melanoma; Pegylated interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; DACARBAZINE; INTERFERON; INTERLEUKIN 2; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; TEMOZOLOMIDE;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DEPRESSION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE ACTIVATION; GENE SILENCING; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MELANOMA; NEOPLASM STAGING; PALLIATIVE CARE; POLYETHYLENE GLYCOLS;

EID: 71049127874     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.004     Document Type: Article

References (31)

1. Caraglia M., Marra M., Pelaia G., et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202 (2005) 323-335
2. Trepiakas R., Pedersen A.E., Met O., et al. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 27 (2009) 2213-2219
3. Glue P., Fang J.W., Rouzier-Panis R., et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68 (2000) 556-567
4. Baker D.E. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord 3 (2003) 93-109
5. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 347 (2002) 975-982
6. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-996
7. Bukowski R., Ernstoff M.S., Gore M.E., et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 20 (2002) 3841-3849
8. Krepler C., Certa U., Wacheck V., et al. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 123 (2004) 664-669
9. Grob J.J., Dreno B., De la Salmoniere P., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (1998) 1905-1910
10. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
11. Kirkwood J.M., Ibrahim J.G., Sondak V.K., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 (2000) 2444-2458
12. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
13. Pehamberger H., Soyer H.P., Steiner A., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16 (1998) 1425-1429
14. Cameron D.A., Cornbleet M.C., MacKie R.M., et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 84 (2001) 1146-1149
15. Cascinelli N., Belli F., MacKie R.M., et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358 (2001) 866-869
16. Eggermont A.M., Suciu S., MacKie R., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005) 1189-1196
17. Hancock B.W., Wheatley K., Harris S., et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22 (2004) 53-61
18. Lens M.B., and Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20 (2002) 1818-1825
19. Wheatley K. Interferon-alpha as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 25 18 Suppl. (2007) 8526
20. Garbe C., and Eigentler T. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17 (2007) 117-127
21. Wheatley K., Ives N., Hancock B., and Gore M. Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. J Clin Oncol 20 (2002) 4120-4121
22. Wheatley K., Ives N., Hancock B., et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29 (2003) 241-252
23. Eggermont A.M.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008) 117-126
24. Bottomley A., Coens C., Suciu S., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 27 (2009) 2916-2923
25. Eigentler T.K., Caroli U.M., Radny P., and Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4 (2003) 748-759
26. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3 (1993) 291-299
27. Dummer R., Garbe C., Thompson J.A., et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 24 (2006) 1188-1194
28. Spieth K., Kaufmann R., Dummer R., et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Annal Oncol 19 (2008) 801-806 [epub 2008 January 4]
29. Hauschild A., Dummer R., Ugurel S., et al. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma. Cancer 113 (2008) 1404-1411
30. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 (2007) 3288-3295
31. Ryan C.W., Goldman B.H., Lara P.N., et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II Study of the Southwest Oncology Group. J Clin Oncol 25 (2007) 3296-3301